A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia

Trial Profile

A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Blinatumomab (Primary) ; Ipilimumab; Nivolumab
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 24 May 2017 Planned End Date changed from 31 Mar 2019 to 5 Nov 2021.
    • 24 May 2017 Planned primary completion date changed from 31 Mar 2019 to 5 Nov 2021.
    • 24 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top